Spyre Therapeutics (SYRE) News Today $25.38 +0.12 (+0.48%) (As of 09:33 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Spyre Therapeutics Added to the Nasdaq Biotechnology IndexDecember 18 at 8:00 AM | prnewswire.comPromising Potential of Spyre Therapeutics’ SPY002 Drives Buy Rating Amid Robust Anti-TL1A MarketDecember 17 at 7:49 PM | markets.businessinsider.comSpyre Therapeutics: Different Name, Same TuneDecember 12, 2024 | seekingalpha.comWellington Management Group LLP Raises Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Wellington Management Group LLP lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 89.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,507,200 shares of the company'December 12, 2024 | marketbeat.comJones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold RecommendationDecember 11, 2024 | msn.comSpyre Therapeutics (NASDAQ:SYRE) Stock, Short Interest ReportDecember 10, 2024 | benzinga.comCharles Schwab Investment Management Inc. Purchases 235,094 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Charles Schwab Investment Management Inc. increased its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 239.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 333,275 shares of the coDecember 10, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $48.57 Average Target Price from BrokeragesDecember 9, 2024 | americanbankingnews.comJanus Henderson Group PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Janus Henderson Group PLC boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 66.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,120,531 shares of the company'sDecember 7, 2024 | marketbeat.comCinctive Capital Management LP Takes $1.80 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Cinctive Capital Management LP acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,256 shaDecember 4, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year pricDecember 4, 2024 | marketbeat.comSPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the FirmDecember 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREDecember 3, 2024 | prnewswire.comSpyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodiesDecember 3, 2024 | msn.comFmr LLC Acquires 115,898 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Fmr LLC grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,623,881 shares of the company's stock after buying an addiDecember 3, 2024 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsDecember 2, 2024 | prnewswire.comSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesDecember 2, 2024 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Walleye Capital LLCWalleye Capital LLC raised its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 61.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 243,372 shares of the company's stock after buying an additional 92,552 shareDecember 1, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LPBraidwell LP cut its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 12.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,189,836 shares of the company's stock after selling 324,702 shares during the period. Spyre Therapeutics accountsNovember 29, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRENovember 25, 2024 | prnewswire.comSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 25, 2024 | prnewswire.comSpyre Therapeutics Inc.November 23, 2024 | wsj.comSpyre Therapeutics revises net loss per share calculationsNovember 20, 2024 | investing.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Should You Sell?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What HappenedNovember 19, 2024 | marketbeat.comSpyre Therapeutics 7.275M share Spot Secondary priced at $27.50November 19, 2024 | markets.businessinsider.comSpyre Therapeutics Faces Internal Control ChallengesNovember 19, 2024 | markets.businessinsider.comSpyre Therapeutics announces $200M common stock offeringNovember 19, 2024 | markets.businessinsider.comSpyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockNovember 18, 2024 | prnewswire.comSpyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsNovember 18, 2024 | prnewswire.comResearch Analysts Set Expectations for SYRE Q1 EarningsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Analysts at Wedbush lowered their Q1 2025 earnings per share (EPS) estimates for Spyre Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.86) per shNovember 15, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)November 14, 2024 | markets.businessinsider.comSpyre Therapeutics price target raised to $65 from $50 at BairdNovember 13, 2024 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)November 13, 2024 | markets.businessinsider.comRobert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock PriceRobert W. Baird raised their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday.November 13, 2024 | marketbeat.comSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance DosingNovember 12, 2024 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024November 11, 2024 | prnewswire.comEquities Analysts Offer Predictions for SYRE Q1 EarningsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Spyre Therapeutics in a report issued on Friday, November 8th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.84) per shareNovember 11, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned a consensus recommendation of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating. The average twelve-month pricNovember 9, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)Wedbush reissued an "outperform" rating and set a $45.00 price objective on shares of Spyre Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comSpyre Therapeutics: Q3 Earnings SnapshotNovember 7, 2024 | sfgate.comSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.com292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Emerald Advisers LLCEmerald Advisers LLC acquired a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 292,569 shares of the company's stock, valued at appNovember 3, 2024 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsNovember 1, 2024 | prnewswire.comSpyre Therapeutics to Participate in Upcoming November Investor ConferencesOctober 30, 2024 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Director Jeffrey W. Albers Sells 300 SharesOctober 29, 2024 | insidertrades.comJeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) StockSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) Director Jeffrey W. Albers sold 300 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $36.43, for a total value of $10,929.00. Following the completion of the transaction, the director now directly owns 34,060 shares in the company, valued at $1,240,805.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.October 28, 2024 | marketbeat.comGuggenheim Raises Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00Guggenheim increased their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Friday.October 25, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?October 25, 2024 | marketbeat.comAssenagon Asset Management S.A. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Assenagon Asset Management S.A. purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,142,768 shares of the company's stock, valued at approximately $33,609,000.October 25, 2024 | marketbeat.comBuy Rating Justified for Spyre Therapeutics Due to Accelerated Drug Development and Promising Preclinical DataOctober 18, 2024 | markets.businessinsider.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.570.65▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼43▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today ACLX News Today ADMA News Today RARE News Today BHVN News Today APLS News Today IMVT News Today SRRK News Today RNA News Today OGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts